NEOG

Business Context and Reporting Period

Company: Neogen Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: May 31, 2011
Business Overview: Neogen develops, manufactures, and markets products dedicated to food and animal safety. Operations are divided into two primary segments: Food Safety (diagnostic test kits for pathogens, toxins, and allergens) and Animal Safety (pharmaceuticals, rodenticides, disinfectants, and genetic testing services). The company operates globally with significant international sales (42.1% of total revenue in 2011).

Key Financial Metrics

Note: The company maintains an unsecured revolving line of credit of $10,000,000 with no outstanding balance as of May 31, 2011.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 23% to $172.7 million, driven by organic growth and the full-year impact of the GeneSeek acquisition (April 2010).
  • Food Safety: Revenue grew 12% to $85.5 million. Allergen revenues surged 45% following the 2009 BioKits acquisition.
  • Animal Safety: Revenue grew 36% to $87.2 million, largely due to GeneSeek contributing over $18 million in its first full year.
• Margin Compression: Consolidated gross margin decreased from 51.9% to 50.8%. This was primarily attributed to the lower historical gross margins of the GeneSeek business model compared to Neogen's core product lines.
• Operating Efficiency: Operating expenses as a percentage of revenue declined from 32.8% to 30.1% due to increased utilization of fixed costs and cost containment programs.
• Other Income/Expense: Shifted from $442,000 income in 2010 to $596,000 expense in 2011. This was driven by a $787,000 charge related to an increase in the secondary payment obligation for the GeneSeek acquisition.

Guidance, Outlook, and Risks

Management Commentary & Outlook:

• Management does not provide specific financial forecasts but remains optimistic about long-term prospects.
• Strategy focuses on internal growth, new product introductions, expanding international sales, and strategic acquisitions.
• Research and Development (R&D) expenditures are expected to remain at approximately 4% to 6% of total revenues.
• Capital expenditures include the construction of a warehouse in Randolph, Wisconsin, and the purchase of a 132,000 sq. ft. facility in Lexington, Kentucky (expected to close August 2011).

Risks and Contingencies:

• Acquisition Integration: Success depends on effectively integrating acquired businesses (e.g., GeneSeek, BioKits).
• International Operations: 42% of revenue is international; exposed to currency fluctuations, regulatory changes, and political instability.
• Intellectual Property: Reliance on patents and trade secrets; risk of infringement litigation or inability to protect proprietary rights.
• Regulatory Environment: Products are subject to strict regulations by the USDA, FDA, and EPA. Changes in regulations could impact costs or marketability.
• Customer Concentration: No single customer exceeded 10% of revenue in 2011 (down from 10.3% in 2010).

Investor Verification Checklist

• GeneSeek Performance: Verify the sustainability of the $18M+ revenue contribution from GeneSeek and the impact of its lower margin profile on future consolidated margins.
• Secondary Payment Obligation: Review the remaining balance of the contingent payment liability for the GeneSeek acquisition (approx. $4.37M as of May 2011) and potential future charges.
• International Exposure: Assess the impact of foreign currency exchange rates (specifically British Pound and Euro) on future earnings, given 42% of sales are international.
• Capital Allocation: Confirm the closing and funding of the Lexington, Kentucky facility purchase ($4.95M) and the impact on cash reserves.
• Patent Portfolio: Review the expiration schedule of key patents (ranging from 2012 to 2028) and the company's strategy for maintaining competitive advantage post-expiration.